Back to search results

Study of Atirmociclib (PF-07220060) in Healthy Volunteers

This study is looking for healthy volunteers to help researchers understand how the drug atirmociclib (PF-07220060) works in the body. Specifically, they want to see if the amount of drug in your system increases proportionally as the dose increases. You can join if you are a healthy adult between 18 and 65 years old, with a Body Mass Index (BMI) between 17.5 and 30.5 kg/m2, and weigh over 110 pounds. The study will measure the drug levels in your blood to see how well different doses are absorbed. This information helps determine the best way to use atirmociclib in the future.

Study design
This is an open-label, two-period, cross-over study involving 72 healthy participants. All participants will receive atirmociclib at different oral doses under fed conditions.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Blood samples will be taken for up to 120 hours (5 days) after each dose to measure drug levels.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07215078

Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants

Completed
PHASE1Ages 18–65InterventionalTreatment
Pfizer
~72 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:atirmociclib (PF-07220060)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
Measured over 1 hour prior to atirmociclib dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose
+1 more outcome measured

Conditions

Healthy Volunteer

Explore related trials

Healthy Volunteer

Where it's being run

1 sites across 1 states
Connecticut1

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)1 hour prior to atirmociclib dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose

    Dose-normalized plasma AUCinf and Cmax of atirmociclib for each cohort (AUClast if AUCinf cannot be estimated)

  • Maximum Observed Plasma Concentration (Cmax)1 hour prior to atirmociclib dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose